Evotec SE

1EVT

Company Profile

  • Business description

    Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

  • Contact

    Essener Bogen 7
    Manfred Eigen Campus
    Hamburg22419
    DEU

    T: +49 40560810

    E: [email protected]

    https://www.evotec.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    4,766

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,777.9050.80-0.58%
CAC 407,878.46111.751.44%
DAX 4024,549.56342.651.42%
Dow JONES (US)44,379.04138.280.31%
FTSE 1008,867.0212.840.15%
HKSE23,892.32255.75-1.06%
NASDAQ20,549.17130.710.64%
Nikkei 22539,821.28132.470.33%
NZX 50 Index12,768.6190.41-0.70%
S&P 5006,248.3722.850.37%
S&P/ASX 2008,538.6052.10-0.61%
SSE Composite Index3,493.054.43-0.13%

Market Movers